Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.61 |
| ▸ | PAK1 | Q13153 | 13/20 | 0.56 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026498 | 0.91 | AXL (0.64) | AXLPAK1TNIKPTK2TTK | |
| SCHEMBL3029413 | 0.90 | AXL (0.75) | AXLPAK1TNIKPTK2TTK | |
| SCHEMBL3032870 | 0.90 | AXL (0.62) | AXLPAK1TNIKPTK2TTK | |
| SCHEMBL3026894 | 0.88 | AXL (0.62) | AXLPAK1TNIKPTK2TTK | |
| SCHEMBL3026503 | 0.88 | AXL (0.65) | AXLPAK1TNIKPTK2TTK | |
| SCHEMBL3022894 | 0.88 | AXL (0.51) | AXLPAK1PTK2TTKBTK | |
| Hydrochloric Acid SCHEMBL3023172 | 0.88 | AXL (0.64) | AXLPAK1TNIKPTK2TTK | |
| SCHEMBL3018290 | 0.87 | AXL (0.63) | AXLPAK1TNIKPTK2TTK | |
| SCHEMBL3026129 | 0.79 | AXL (0.57) | AXLPAK1TNIKEGFR | |
| SCHEMBL3032288 | 0.78 | AXL (0.50) | AXLPAK1TNIKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102307875-A | Pyrrolopyrimidinyl axl kinase inhibitors | SUPERGEN INC | 2012-01-04 | — | — | CN | disclosed |
| EP-2393814-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SuperGen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | AXL, FLT3, TYRO3 | AXL 1/4885PAK1 22/4885TNIK 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.